De Angelis Sara, Conti Alessio, Di Nunzio Antonella, Stoppa Patrizia, Zanchi Fabiano, Dimonte Valerio
North-West District, Azienda Sanitaria Locale Città di Torino, 10146 Torino, Italy.
University Center of Excellence on Nephrologic, Rheumatologic, and Rare Diseases, Azienda Sanitaria Locale Città di Torino, 10146 Torino, Italy.
Healthcare (Basel). 2025 Jul 9;13(14):1652. doi: 10.3390/healthcare13141652.
: Hard-to-heal wounds are resistant to standard treatments and significantly impact patients' quality of life and healthcare costs. Photobiomodulation with blue light has shown potential in wound healing, but evidence in wounds persisting for extended periods is limited. This pilot study evaluated the effectiveness of an accelerated photobiomodulation protocol in patients with hard-to-heal wounds in a nurse-led outpatient setting. : Eleven patients with venous, lymphatic, diabetic, or mixed etiology wounds, unhealed for at least two years, were recruited from two clinics in the North District of the ASL Città di Torino. Participants received twice-weekly sessions of blue light photobiomodulation (EmoLED™, 400-430 nm lasting 60-120 s) for four weeks, in addition to standard care. The wound area was measured at baseline, week 4, and week 12 using the CutiMed Wound Navigator Version 2.2.8. The secondary endpoints included pain, wound exudate quantity and quality, and the surrounding skin condition. : All participants (average wound duration 5.9 years; mean area 13.1 cm, SD ± 14.4) completed the treatment; two were lost at follow-up due to unrelated clinical events. No adverse reactions were reported. At week 4, an area reduction was shown in 9 of 11 wounds (mean: 9.5 cm, SD ± 11.4), though not statistically significant ( = 0.240). At week 12, a significant reduction was observed (mean: 7.2 cm, SD ± 13; = 0.04), with a mean percentage area decrease of 40.5%. Significant improvements were also noted in pain levels, exudate characteristics, and surrounding skin conditions over time. : Accelerated blue light photobiomodulation appears to support long-term wound healing and symptom improvement in patients with hard-to-heal wounds. These findings warrant confirmation in larger, controlled studies.
难愈合伤口对标准治疗有抗性，会显著影响患者的生活质量并增加医疗成本。蓝光光生物调节疗法在伤口愈合方面已显示出潜力，但对于长期存在的伤口，相关证据有限。本前瞻性研究在护士主导的门诊环境中评估了加速光生物调节方案对难愈合伤口患者的有效性。从都灵市ASL北区的两家诊所招募了11名患有静脉性、淋巴性、糖尿病性或混合病因伤口且至少两年未愈合的患者。参与者除接受标准护理外，还每周接受两次蓝光光生物调节治疗（EmoLED™，400 - 430纳米，持续60 - 120秒），为期四周。在基线、第4周和第12周使用CutiMed伤口导航仪2.2.8版测量伤口面积。次要终点包括疼痛、伤口渗出物的数量和质量以及周围皮肤状况。所有参与者（平均伤口持续时间5.9年；平均面积13.1平方厘米，标准差±14.4）均完成了治疗；两名患者因无关临床事件在随访中失访。未报告不良反应。在第4周时，11处伤口中有9处显示面积缩小（平均：9.5平方厘米，标准差±11.4），但无统计学意义（P = 0.240）。在第12周时，观察到显著缩小（平均：7.2平方厘米，标准差±13；P = 0.04），平均面积减少百分比为40.5%。随着时间推移，疼痛水平、渗出物特征和周围皮肤状况也有显著改善。加速蓝光光生物调节似乎有助于难愈合伤口患者的长期伤口愈合和症状改善。这些发现有待在更大规模的对照研究中得到证实。
